MARKET

ZTS

ZTS

Zoetis
NYSE

Real-time Quotes | Nasdaq Last Sale

164.08
-0.26
-0.16%
Opening 10:27 11/24 EST
OPEN
164.90
PREV CLOSE
164.34
HIGH
166.18
LOW
163.48
VOLUME
283.45K
TURNOVER
--
52 WEEK HIGH
176.64
52 WEEK LOW
90.14
MARKET CAP
77.98B
P/E (TTM)
47.11
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Zoetis is First Animal Health Company to Issue Environmental, Social and Governance (ESG) Review Based on Leading Sustainability Frameworks
Zoetis is the first animal health company to issue Environmental, Social and Governance (ESG) Review based on leading sustainability frameworks.
Business Wire · 11/16 13:00
Price Over Earnings Overview: Zoetis
In the current session, Zoetis Inc. (NYSE: ZTS) is trading at $165.76, after a 0.26% gain. Over the past month, the stock increased by 1.45%, and in the past year, by 39.66%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently under from its 52 week high by 6.16%. The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E indicates that shareholders do not expect the stock to perform better in the future, and that the company is probably undervalued. It shows that shareholders are less than willing to pay a high share price, because they do not expect the company to exhibit growth, in terms of future earnings. View more earnings on ZTSDepending on the particular phase of a business cycle, some industries will perform better than others. Zoetis Inc. has a better P/E ratio of 47.61 than the aggregate P/E ratio of 35.46 of the Pharmaceuticals industry. Ideally, one might believe that Zoetis Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. There are many limitations to P/E ratio. It is sometimes difficult to determine the nature of the earnings makeup of a company. Shareholders might not get what they're looking for, from trailing earnings.See more from Benzinga * Click here for options trades from Benzinga * Stocks That Hit 52-Week Highs On Thursday * Stocks That Hit 52-Week Highs On Wednesday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 11/13 14:54
Zoetis (ZTS) Librela Gets Marketing Authorization in Europe
Zoetis (ZTS) gets marketing authorization for Librela, for monthly alleviation of osteoarthritis pain in dogs.
Zacks · 11/13 14:42
Morgan Stanley Maintains Equal-Weight on Zoetis, Raises Price Target to $174
Morgan Stanley maintains Zoetis (NYSE:ZTS) with a Equal-Weight and raises the price target from $167 to $174.
Benzinga · 11/13 13:32
Zoetis osteoarthritis pain med for dogs OK'd in Europe
The European Commission approves Zoetis' (ZTS) once-per-month monoclonal antibody (mAb), Librela (bedinvetmab), for alleviation of osteoarthritis pain in dogs, by inhibiting nerve growth factor, a key player in osteoarthritis pain.The company says that
Seekingalpha · 11/12 13:21
Zoetis Receives European Commission Marketing Authorization for Librela
The first injectable monoclonal antibody authorized for alleviation of osteoarthritis pain in dogs Librela works differently from other pain medications, combining one month of pain control and increased mobility,
Benzinga · 11/12 13:13
Zoetis Receives European Commission Marketing Authorization for Librela® (bedinvetmab)
Zoetis has received European Commission Marketing Authorization for Librela (bedinvetmab) for alleviation of osteoarthritis (OA) pain in dogs
Business Wire · 11/12 13:00
Earnings Beat: Zoetis Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Zoetis Inc. (NYSE:ZTS) just released its quarterly report and things are looking bullish. It was overall a positive...
Simply Wall St. · 11/09 19:52
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ZTS. Analyze the recent business situations of Zoetis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 20 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ZTS stock price target is 185.00 with a high estimate of 210.00 and a low estimate of 159.00.
EPS
Institutional Holdings
Institutions: 1.63K
Institutional Holdings: 463.31M
% Owned: 97.48%
Shares Outstanding: 475.27M
TypeInstitutionsShares
Increased
496
14.93M
New
169
-95.94K
Decreased
470
14.91M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.44%
Pharmaceuticals & Medical Research
+0.14%
Key Executives
Non-Executive Chairman/Independent Director
Michael McCallister
Chief Executive Officer/Director
Kristin Peck
Chief Financial Officer/Executive Vice President
Glenn David
Chief Human Resource Officer/Executive Vice President
Roxanne Lagano
Executive Vice President/General Counsel/Secretary
Heidi Chen
Executive Vice President
Catherine Knupp
Executive Vice President
Roman Trawicki
Independent Director
Paul Bisaro
Independent Director
Frank D'Amelio
Independent Director
Sanjay Khosla
Independent Director
Gregory Norden
Independent Director
Louise Parent
Independent Director
Willie Reed
Independent Director
Linda Rhodes
Independent Director
Robert Scully
Independent Director
William Steere
  • Dividends
  • Splits
  • Insider Activity
Declaration Date
Dividend Per Share
Ex-Div Date
10/07/2020
Dividend USD 0.2
10/20/2020
05/20/2020
Dividend USD 0.2
07/16/2020
02/11/2020
Dividend USD 0.2
04/16/2020
12/11/2019
Dividend USD 0.2
01/16/2020
10/03/2019
Dividend USD 0.164
10/21/2019
05/15/2019
Dividend USD 0.164
07/18/2019
02/12/2019
Dividend USD 0.164
04/17/2019
12/12/2018
Dividend USD 0.164
01/17/2019
10/10/2018
Dividend USD 0.126
11/19/2018
05/15/2018
Dividend USD 0.126
07/19/2018
02/13/2018
Dividend USD 0.126
04/19/2018
12/11/2017
Dividend USD 0.126
01/18/2018
10/05/2017
Dividend USD 0.105
11/08/2017
05/22/2017
Dividend USD 0.105
06/13/2017
02/15/2017
Dividend USD 0.105
04/04/2017
12/07/2016
Dividend USD 0.105
01/18/2017
10/06/2016
Dividend USD 0.095
11/01/2016
05/13/2016
Dividend USD 0.095
06/28/2016
02/22/2016
Dividend USD 0.095
04/05/2016
12/18/2015
Dividend USD 0.095
01/19/2016
10/01/2015
Dividend USD 0.083
11/03/2015
07/21/2015
Dividend USD 0.083
08/11/2015
02/27/2015
Dividend USD 0.083
04/07/2015
12/17/2014
Dividend USD 0.083
01/20/2015
10/02/2014
Dividend USD 0.072
11/03/2014
07/31/2014
Dividend USD 0.072
08/18/2014
03/27/2014
Dividend USD 0.072
04/24/2014
12/19/2013
Dividend USD 0.072
01/28/2014
09/13/2013
Dividend USD 0.065
10/30/2013
06/21/2013
Dividend USD 0.065
07/30/2013
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ZTS
Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Zoetis Inc stock information, including NYSE:ZTS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZTS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZTS stock methods without spending real money on the virtual paper trading platform.